This generation of scientists, clinicians and bioinformaticians have already elevated the standards for diagnosis, prediction and care, ultimately improving patient outcome for millions of people by leveraging genomic information. This trend is only going to continue. Next-gen sequencing has made its way into the clinic. Golden Helix supports the adoption of Precision Medicine by building products, such as our VarSeq Clinical Suite, that help to welcome in the next frontier of medical care.
In my latest eBook, NGS-Based Clinical Testing, we cover our best understanding on how this revolution in clinical diagnostics will unfold. It reviews critical success factors for the clinical adoption of next-gen sequencing technology. In addition, we go into more detail on how the various parts of a clinical pipeline are implemented, vetted and maintained.
The eBook gives an overview of all key processes and procedures, as well as best practices regarding NGS-based clinical testing. It reviews the wet bench process and discusses the building blocks of a clinical NGS pipeline. There is a separate chapter that focuses entirely on clinical reporting. I also spend some time explaining in detail what Golden Helix’s value proposition looks like in this area.
Along with this new eBook launch, we just conducted a webinar on clinical reporting. Please see the recording of this webinar here.
A lot of people at Golden Helix have contributed to this eBook. It would have been impossible to write this without the ingenious work of our product developers and field scientists. Specifically, I’d like to thank Steven Hystad, Gabe Rudy and Cheryl Rogers for their invaluable contributions.
Dr. Andreas Scherer is CEO of Golden Helix. The company has been delivering industry leading bioinformatics solutions for the advancement of life science research and translational medicine for over a decade. Its innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from next-generation sequencing. With its solutions, hundreds of the world’s hospitals and testing labs are able to harness the full potential of genomics to identify the cause of disease, develop genomic diagnostics, and advance the quest for personalized medicine. Golden Helix products and services have been cited in thousands of peer-reviewed publications. Golden Helix is also on the Inc 5000 list of the fastest-growing private companies in the US.
He is also Managing Partner of Salto Partners, Inc, a management consulting firm headquartered in Nevada. He has extensive experience successfully managing growth as well as orchestrating complex turnaround situations. His company, Salto Partners, advises on business strategy, financing, sales, and operations. Clients are operating in the high-tech and life sciences space.
Dr. Scherer holds a Ph.D. in computer science from the University of Hagen, Germany, and a Master of Computer Science from the University of Dortmund, Germany. He is author and co- author of over 20 international publications and has written books on project management, the Internet, and artificial intelligence. His latest book, “Be Fast Or Be Gone”, is a prizewinner in the 2012 Eric Hoffer Book Awards competition, and has been named a finalist in the 2012 Next Generation Indie Book Awards!
Thank you for sharing it with us. Next-generation sequencing based clinical testing will make mark in the future clinical trials.